Table 1.
Clinicopathological characteristics of patients with GS, CIN-intestinal, and CIN-diffuse/mixed tumors.
| GS-intestinal | GS-diffuse | CIN-intestinal | CIN-diffuse | P value | |
|---|---|---|---|---|---|
| (n = 24) | (n = 57) | (n = 142) | (n = 86) | ||
| Age | 0.019 | ||||
| Mean (range) | 63.0 (42–83) | 60.9 (33–80) | 65.9 (21–84) | 62.6 (31–84) | |
| Sex | 0.0023 | ||||
| Male | 9 (37.5%) | 23 (40.4%) | 91 (64.1%) | 40 (46.5%) | |
| Female | 15 (62.5%) | 34 (59.6%) | 51 (35.9%) | 46 (53.5%) | |
| Tumor localization | 0.24 | ||||
| Proximal | 4 (16.7%) | 3 (5.3%) | 15 (10.6%) | 8 (9.3%) | |
| Middle | 8 (33.3%) | 16 (28.1%) | 36 (25.4%) | 21 (24.4%) | |
| Distal | 11 (45.8%) | 29 (50.9%) | 80 (56.3%) | 41 (47.7%) | |
| >2/3 of stomach | 1 (4.2%) | 9 (15.8%) | 11 (7.7%) | 16 (18.6%) | |
| pT stage | 0.00050 | ||||
| pT1 | 13 (54.2%) | 17 (29.8%) | 24 (16.9%) | 5 (5.8%) | |
| pT2 | 1 (4.2%) | 6 (10.5%) | 20 (14.1%) | 11 (12.8%) | |
| pT3 | 6 (25.0%) | 19 (33.3%) | 62 (43.7%) | 31 (36.0%) | |
| pT4 | 4 (16.7%) | 15 (26.3%) | 36 (25.4%) | 38 (44.2%) | |
| Missings | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 1 (1.2%) | |
| pN stage | 0.0045 | ||||
| pN0 | 14 (58.3%) | 23 (40.4%) | 44 (31.0%) | 18 (20.9%) | |
| pN1 | 3 (12.5%) | 7 (12.3%) | 32 (22.5%) | 16 (18.6%) | |
| pN2 | 2 (8.3%) | 14 (24.6%) | 39 (27.5%) | 18 (20.9%) | |
| pN3 | 5 (20.8%) | 13 (22.8%) | 27 (19.0%) | 34 (39.5%) | |
| TNM (7th edition) | 0.0010 | ||||
| Stage I | 13 (54.2%) | 17 (29.8%) | 33 (23.2%) | 9 (10.5%) | |
| Stage II | 4 (16.7%) | 15 (26.3%) | 39 (27.5%) | 20 (23.3%) | |
| Stage III | 6 (25.0%) | 24 (42.1%) | 67 (47.2%) | 50 (58.1%) | |
| Stage IV | 1 (4.2%) | 1 (1.8%) | 3 (2.1%) | 7 (8.1%) | |
| p53 IHC | 0.00011 | ||||
| Normal expression | 8 (33.3%) | 27 (47.4%) | 25 (17.6%) | 24 (27.6%) | |
| Aberrant expression | 5 (20.8%) | 7 (12.3%) | 48 (33.8%) | 29 (33.7%) | |
| Missings | 11 (45.8%) | 23 (40.4%) | 69 (48.6%) | 33 (38.4%) | |
| CDH1 IHC | 0.092 | ||||
| Normal expression | 11 (45.8%) | 28 (49.1%) | 71 (50.0%) | 49 (57.0%) | |
| Aberrant expression | 3 (12.5%) | 7 (12.3%) | 5 (3.5%) | 9 (10.5%) | |
| Missings | 10 (41.7%) | 22 (38.6%) | 66 (46.5%) | 28 (32.6%) | |
| Genome Instability Index | <0.0001 | ||||
| GII-low | 15 (62.5%) | 45 (78.9%) | 5 (3.5%) | 8 (9.3%) | |
| GII-high | 9 (37.5%) | 12 (21.1%) | 137 (96.5%) | 78 (90.7%) |
Data are presented as number (percentage) of patients unless otherwise indicated.
GS genomically stable, CIN chromosomal instable, IHC immunohistochemistry, GII Genome Instability Index.